Longeveron Inc (LGVN)

$0.69 -0.04 (-5.29%)
Market Cap 21.51M
Revenue (ttm) 1.20M
Net Income (ttm) -22.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,891.67%
Debt to Equity Ratio 0.05
Volume 363,300
Avg Vol 332,996
Day's Range N/A - N/A
Shares Out 31.15M
Stochastic %K 6%
Beta -0.35
Analysts Strong Sell
Price Target $7.15

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 470 2550
Address:
Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States
Huskersnsaints
Huskersnsaints Jul. 2 at 6:08 PM
$LGVN does anyone have the idea of the execution of these companies product lines? Is the stock just dead or what it seems like it has so much going for it. It just will not move up.
2 · Reply
eastman71
eastman71 Jun. 25 at 3:29 PM
$LGVN I’d like you to say why you think it’s going to explode. Thanks.
0 · Reply
Kingdaley
Kingdaley Jun. 25 at 3:12 PM
$LGVN here is goes better get in
1 · Reply
Kingdaley
Kingdaley Jun. 25 at 3:10 PM
$LGVN about to explode soon
1 · Reply
odjfa
odjfa Jun. 25 at 7:28 AM
$LGVN $LGVN As a former bag holder, I feel bad for those still holding. 💎 Diamond hands
1 · Reply
BOUDIN420
BOUDIN420 Jun. 25 at 2:07 AM
$LGVN ww from .74
0 · Reply
Huskersnsaints
Huskersnsaints Jun. 24 at 8:06 PM
$LGVN This and scnx to great product line but for some reason the share price just gets destroyed every day crap stock move 100-1000% but this just drift lower every freaken day!!!!!
0 · Reply
Ueberschlaefer
Ueberschlaefer Jun. 24 at 3:35 AM
$LGVN is the company logo a human head and arm crawling out of a birth canal? is it like something to do with a live birth? or is it just a lab!@ with a cl!tor3s? who designed this? why?
0 · Reply
focafoca99
focafoca99 Jun. 18 at 1:32 PM
$LGVN present additional Phase 2a clinical data on laromestrocel at the AAIC poster session on July 13.
0 · Reply
HoldingontoPennies
HoldingontoPennies Jun. 17 at 3:45 PM
$LGVN
0 · Reply
Latest News on LGVN
Longeveron Transcript: AGM 2026

Jul 1, 2026, 11:00 AM EDT - 3 days ago

Longeveron Transcript: AGM 2026

New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC)

Jun 18, 2026, 9:20 AM EDT - 16 days ago

New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC)

Longeveron granted SME status by European Medicines Agency

2026-06-09T13:29:08.000Z - 25 days ago

Longeveron granted SME status by European Medicines Agency

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

Jun 9, 2026, 9:20 AM EDT - 25 days ago

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

Longeveron to Present at BIO International Convention 2026

Jun 4, 2026, 9:15 AM EDT - 4 weeks ago

Longeveron to Present at BIO International Convention 2026

Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

May 20, 2026, 4:05 PM EDT - 6 weeks ago

Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

Longeveron Proxy statement: Proxy filing

May 20, 2026, 8:00 AM EDT - 6 weeks ago

Longeveron Proxy statement: Proxy filing

Longeveron Proxy statement: Proxy filing

May 20, 2026, 8:00 AM EDT - 6 weeks ago

Longeveron Proxy statement: Proxy filing

Longeveron reports Q1 EPS (19c) vs. (34c) last year

2026-05-13T21:35:38.000Z - 7 weeks ago

Longeveron reports Q1 EPS (19c) vs. (34c) last year

Longeveron Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 7 weeks ago

Longeveron Earnings Call Transcript: Q1 2026

Longeveron Quarterly report: Q1 2026

May 13, 2026, 4:30 PM EDT - 7 weeks ago

Longeveron Quarterly report: Q1 2026

Longeveron Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 7 weeks ago

Longeveron Earnings release: Q1 2026

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

May 13, 2026, 4:05 PM EDT - 7 weeks ago

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

Longeveron Slides: Investor presentation

May 13, 2026, 7:00 AM EDT - 7 weeks ago

Longeveron Slides: Investor presentation

Longeveron reports DMC approval for laromestrocel study to continue as designed

2026-05-11T20:09:41.000Z - 7 weeks ago

Longeveron reports DMC approval for laromestrocel study to continue as designed

Longeveron downgraded to Hold from Buy at Maxim

2026-05-11T15:43:29.000Z - 7 weeks ago

Longeveron downgraded to Hold from Buy at Maxim

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

May 11, 2026, 9:10 AM EDT - 7 weeks ago

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron provides update on laromestrocel development after Type C meeting

2026-05-08T22:59:18.000Z - 2 months ago

Longeveron provides update on laromestrocel development after Type C meeting

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

May 8, 2026, 4:05 PM EDT - 2 months ago

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

May 5, 2026, 4:15 PM EDT - 2 months ago

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

Longeveron Proxy statement: Proxy filing

May 5, 2026, 8:00 AM EDT - 2 months ago

Longeveron Proxy statement: Proxy filing

Longeveron Slides: Investor presentation

May 4, 2026, 7:00 AM EDT - 2 months ago

Longeveron Slides: Investor presentation

Longeveron price target lowered to $8 from $10 at H.C. Wainwright

2026-05-04T10:15:51.000Z - 2 months ago

Longeveron price target lowered to $8 from $10 at H.C. Wainwright

Longeveron files to sell 30.87M shares of Class A common stock for holders

2026-04-10T20:05:14.000Z - 3 months ago

Longeveron files to sell 30.87M shares of Class A common stock for holders

Longeveron Registration statement: Registration filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Longeveron Registration statement: Registration filing

Longeveron granted Chinese patent for potency assay methods

2026-04-08T13:38:32.000Z - 3 months ago

Longeveron granted Chinese patent for potency assay methods

Longeveron granted Chinese patent for potency assay methods

2026-04-08T13:27:11.000Z - 3 months ago

Longeveron granted Chinese patent for potency assay methods

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Apr 8, 2026, 9:15 AM EDT - 3 months ago

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron Slides: Investor presentation

Apr 1, 2026, 7:00 AM EDT - 3 months ago

Longeveron Slides: Investor presentation

Longeveron price target lowered to $2 from $3 at Roth Capital

2026-03-18T23:20:16.000Z - 3 months ago

Longeveron price target lowered to $2 from $3 at Roth Capital

Longeveron Earnings Call Transcript: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 3 months ago

Longeveron Earnings Call Transcript: Q4 2025

Longeveron Earnings release: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 3 months ago

Longeveron Earnings release: Q4 2025

Longeveron Annual report: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 3 months ago

Longeveron Annual report: Q4 2025

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Mar 17, 2026, 4:05 PM EDT - 3 months ago

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Longeveron Slides: Investor presentation

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Longeveron Slides: Investor presentation

Longeveron Announces Closing of Private Placement of up to $30 Million

Mar 11, 2026, 4:05 PM EDT - 4 months ago

Longeveron Announces Closing of Private Placement of up to $30 Million

3 Penny Stocks to Watch Now, 3/11/26

2026-03-11T14:11:00.000Z - 4 months ago

3 Penny Stocks to Watch Now, 3/11/26

ATPC INKT

Longeveron prices 6.01M shares at 52c in private placement

2026-03-10T13:16:09.000Z - 4 months ago

Longeveron prices 6.01M shares at 52c in private placement

Longeveron Proxy statement: Proxy Filing

Mar 3, 2026, 7:00 AM EST - 4 months ago

Longeveron Proxy statement: Proxy Filing

Longeveron: Phase 2b results show laromestrocel improved physical condition

2026-02-25T16:10:58.000Z - 4 months ago

Longeveron: Phase 2b results show laromestrocel improved physical condition

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

Feb 25, 2026, 11:05 AM EST - 4 months ago

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

Longeveron names Stephen Willard as CEO, succeeding Than Powell

2026-02-13T21:35:23.000Z - 5 months ago

Longeveron names Stephen Willard as CEO, succeeding Than Powell

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Feb 13, 2026, 4:30 PM EST - 5 months ago

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Longeveron ‘applauds’ Mikaela Naylon Give Kids a Chance Act passage

2026-02-05T14:21:01.000Z - 5 months ago

Longeveron ‘applauds’ Mikaela Naylon Give Kids a Chance Act passage

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Feb 5, 2026, 9:15 AM EST - 5 months ago

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Longeveron granted Japan patent for potency assay methods for MSCs

2026-01-29T14:21:08.000Z - 5 months ago

Longeveron granted Japan patent for potency assay methods for MSCs

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Jan 29, 2026, 9:15 AM EST - 5 months ago

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron granted FDA Type C Meeting ahead of ELPIS II data readout

2026-01-26T14:21:24.000Z - 5 months ago

Longeveron granted FDA Type C Meeting ahead of ELPIS II data readout

Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Dec 29, 2025, 9:15 AM EST - 6 months ago

Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Longeveron granted U.S. patent for method of treating female sexual dysfunction

2025-12-17T14:20:32.000Z - 7 months ago

Longeveron granted U.S. patent for method of treating female sexual dysfunction

Longeveron granted Canadian patent covering laromestrocel administration

2025-12-02T14:25:12.000Z - 7 months ago

Longeveron granted Canadian patent covering laromestrocel administration

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Dec 2, 2025, 9:15 AM EST - 7 months ago

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Longeveron to present MRI biomarker data in Alzheimer’s at CTAD 2025

2025-12-01T17:10:18.000Z - 7 months ago

Longeveron to present MRI biomarker data in Alzheimer’s at CTAD 2025

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Dec 1, 2025, 12:00 PM EST - 7 months ago

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Nov 19, 2025, 9:15 AM EST - 8 months ago

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Nov 12, 2025, 9:05 AM EST - 8 months ago

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Longeveron Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Longeveron Earnings Call Transcript: Q3 2025

Longeveron Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Longeveron Earnings release: Q3 2025

Longeveron Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 8 months ago

Longeveron Quarterly report: Q3 2025

Longeveron Slides: Corporate Presentation

Nov 4, 2025, 4:00 PM EST - 8 months ago

Longeveron Slides: Corporate Presentation

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Oct 27, 2025, 9:15 AM EDT - 8 months ago

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Oct 6, 2025, 9:15 AM EDT - 9 months ago

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 22, 2025, 9:15 AM EDT - 10 months ago

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron® Announces Key Leadership Updates

Sep 3, 2025, 4:05 PM EDT - 10 months ago

Longeveron® Announces Key Leadership Updates

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 9:15 AM EDT - 11 months ago

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron Earnings Call Transcript: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 11 months ago

Longeveron Earnings Call Transcript: Q2 2025

Longeveron Earnings release: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 11 months ago

Longeveron Earnings release: Q2 2025

Longeveron Quarterly report: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 11 months ago

Longeveron Quarterly report: Q2 2025

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 13, 2025, 4:05 PM EDT - 11 months ago

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Longeveron Slides: Investor Presentation

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Longeveron Slides: Investor Presentation

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Aug 11, 2025, 4:15 PM EDT - 11 months ago

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron Announces Up To $17.5 Million Public Offering

Aug 8, 2025, 1:28 PM EDT - 11 months ago

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 11 months ago

Longeveron Registration statement: Registration Filing

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Aug 5, 2025, 9:15 AM EDT - 11 months ago

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Longeveron Registration statement: Registration Filing

Aug 4, 2025, 8:00 AM EDT - 11 months ago

Longeveron Registration statement: Registration Filing

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Jul 21, 2025, 9:15 AM EDT - 1 year ago

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Jul 8, 2025, 9:15 AM EDT - 1 year ago

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Longeveron® Appoints Than Powell as Chief Business Officer

Jun 26, 2025, 9:05 AM EDT - 1 year ago

Longeveron® Appoints Than Powell as Chief Business Officer

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Jun 24, 2025, 6:30 AM EDT - 1 year ago

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Transcript: AGM 2025

Jun 13, 2025, 1:00 PM EDT - 1 year ago

Longeveron Transcript: AGM 2025

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 9, 2025, 9:15 AM EDT - 1 year ago

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Longeveron® to Attend BIO International Convention 2025

May 20, 2025, 9:15 AM EDT - 1 year ago

Longeveron® to Attend BIO International Convention 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 12, 2025, 7:15 AM EDT - 1 year ago

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Earnings Call Transcript: Q1 2025

Longeveron Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Earnings release: Q1 2025

Longeveron Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Quarterly report: Q1 2025

Longeveron Slides: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Slides: Q1 2025

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

May 2, 2025, 8:30 AM EDT - 1 year ago

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Longeveron Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Longeveron Proxy statement: Proxy Filing

Longeveron Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Longeveron Proxy statement: Proxy Filing

Longeveron Registration statement: Registration Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Longeveron Registration statement: Registration Filing

Longeveron Transcript: 37th Annual ROTH Conference

Mar 18, 2025, 12:00 PM EDT - 1 year ago

Longeveron Transcript: 37th Annual ROTH Conference

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Longeveron® to Present at the 37th Annual Roth Conference

Mar 5, 2025, 9:25 AM EST - 1 year ago

Longeveron® to Present at the 37th Annual Roth Conference

Longeveron Earnings Call Transcript: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Earnings Call Transcript: Q4 2024

Longeveron Earnings release: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Earnings release: Q4 2024

Longeveron Annual report: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Annual report: Q4 2024

Longeveron Slides: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Slides: Q4 2024

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Feb 28, 2025, 4:04 PM EST - 1 year ago

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron Transcript: Emerging Growth Conference 79

Feb 19, 2025, 3:10 PM EST - 1 year ago

Longeveron Transcript: Emerging Growth Conference 79

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Feb 18, 2025, 9:25 AM EST - 1 year ago

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Longeveron Transcript: Biotech Showcase 2025

Jan 14, 2025, 7:00 PM EST - 1 year ago

Longeveron Transcript: Biotech Showcase 2025

Longeveron to Present at Biotech Showcase 2025

Dec 18, 2024, 9:10 AM EST - 1 year ago

Longeveron to Present at Biotech Showcase 2025

Longeveron Transcript: Emerging Growth Conference77

Dec 5, 2024, 12:00 PM EST - 1 year ago

Longeveron Transcript: Emerging Growth Conference77

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Dec 2, 2024, 9:05 AM EST - 1 year ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Longeveron Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Longeveron Earnings Call Transcript: Q3 2024

Longeveron Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Longeveron Quarterly report: Q3 2024

Longeveron Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Longeveron Earnings release: Q3 2024

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Nov 11, 2024, 9:05 AM EST - 1 year ago

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 27, 2024, 3:10 PM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 14, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Huskersnsaints
Huskersnsaints Jul. 2 at 6:08 PM
$LGVN does anyone have the idea of the execution of these companies product lines? Is the stock just dead or what it seems like it has so much going for it. It just will not move up.
2 · Reply
eastman71
eastman71 Jun. 25 at 3:29 PM
$LGVN I’d like you to say why you think it’s going to explode. Thanks.
0 · Reply
Kingdaley
Kingdaley Jun. 25 at 3:12 PM
$LGVN here is goes better get in
1 · Reply
Kingdaley
Kingdaley Jun. 25 at 3:10 PM
$LGVN about to explode soon
1 · Reply
odjfa
odjfa Jun. 25 at 7:28 AM
$LGVN $LGVN As a former bag holder, I feel bad for those still holding. 💎 Diamond hands
1 · Reply
BOUDIN420
BOUDIN420 Jun. 25 at 2:07 AM
$LGVN ww from .74
0 · Reply
Huskersnsaints
Huskersnsaints Jun. 24 at 8:06 PM
$LGVN This and scnx to great product line but for some reason the share price just gets destroyed every day crap stock move 100-1000% but this just drift lower every freaken day!!!!!
0 · Reply
Ueberschlaefer
Ueberschlaefer Jun. 24 at 3:35 AM
$LGVN is the company logo a human head and arm crawling out of a birth canal? is it like something to do with a live birth? or is it just a lab!@ with a cl!tor3s? who designed this? why?
0 · Reply
focafoca99
focafoca99 Jun. 18 at 1:32 PM
$LGVN present additional Phase 2a clinical data on laromestrocel at the AAIC poster session on July 13.
0 · Reply
HoldingontoPennies
HoldingontoPennies Jun. 17 at 3:45 PM
$LGVN
0 · Reply
HoldingontoPennies
HoldingontoPennies Jun. 14 at 10:45 AM
$LGVN 👀
0 · Reply
focafoca99
focafoca99 Jun. 9 at 1:58 PM
$LGVN granted EMA SME status, giving it regulatory benefits for its stem cell therapies.
0 · Reply
Threepence
Threepence Jun. 9 at 1:34 PM
$LGVN
0 · Reply
janlukas
janlukas Jun. 9 at 9:21 AM
$LGVN I've already said that if Lgvn develops even just temporarily halfway its pipeline is worth between $50 and $80, if then everything goes well then it reaches three-digit values.
1 · Reply
hellomynameiz
hellomynameiz Jun. 8 at 3:36 PM
$LGVN
1 · Reply
nhyujm6
nhyujm6 Jun. 3 at 4:01 PM
$LGVN Not discussed here, but new CEO is a money/deal maker guy
1 · Reply
HoldingontoPennies
HoldingontoPennies Jun. 3 at 3:50 PM
$LGVN
0 · Reply
hellomynameiz
hellomynameiz Jun. 3 at 12:06 PM
$LGVN 10000 shares
0 · Reply
janlukas
janlukas Jun. 1 at 1:23 PM
$LGVN Today Tghl +500% at the opening. I'm waiting for Lgvn to reach triple digits with this pipeline.
0 · Reply
coolcoo
coolcoo May. 28 at 3:04 PM
$LGVN holo is squeezing now 🔥🔥🔥🔥
0 · Reply
janlukas
janlukas May. 28 at 10:54 AM
$LGVN Let's clarify one point: shareholders were asked for prior authorization from the shareholders' meeting, but the CONFIRMATION MEETING WAS CANCELLED. This is a great signal from the manager; if his pipeline results are good, he could reach a three-figure value, with a billion-dollar market cap, as there is currently no cure for pediatric heart disease.
1 · Reply
poilu
poilu May. 27 at 11:41 AM
$LGVN Received notification from my platform on a vote.....I've not paid attention in so long I don't even know what we're voting for.
1 · Reply